AssetMark Inc’s Ascendis Pharma A/S ASND Stock Holding History

AssetMark Inc’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.6M	Buy	13,495 +3,860	+40%	+$902K	0.01%	823
2026 Q1	$2.2M	Buy	9,635 +1,056	+12%	+$237K	﹤0.01%	865
2025 Q4	$1.83M	Buy	8,579 +2,787	+48%	+$576K	﹤0.01%	875
2025 Q3	$1.15M	Buy	5,792 +3,414	+144%	+$637K	﹤0.01%	945
2025 Q2	$410K	Buy	2,378 +2,309	+3,346%	+$376K	﹤0.01%	1083
2025 Q1	$10.8K	Sell	69 -2,873	-98%	-$410K	﹤0.01%	1839
2024 Q4	$405K	Buy	2,942 +728	+33%	+$95.7K	﹤0.01%	988
2024 Q3	$331K	Buy	+2,214	New	+$299K	﹤0.01%	944

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

AssetMark Inc's ASND Position: Q2 2026 in Review

AssetMark Inc increased its Ascendis Pharma A/S (ASND) stake by 40% in Q2 2026, buying an estimated $902K and bringing the position to 13,495 shares worth $3.6M. The position accounts for 0.01% of the portfolio, ranked #823.

AssetMark Inc first reported a position in ASND in Q3 2024 and has held it in 8 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

AssetMark Inc held 13,495 shares of Ascendis Pharma A/S worth $3.6M as of Q2 2026.
AssetMark Inc bought 3,860 Ascendis Pharma A/S shares in Q2 2026, an estimated $902K.
Ascendis Pharma A/S made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #823 holding.
AssetMark Inc first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 8 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.